Ionis Pharmaceuticals Inc. (IONS)

51.02
1.01 2.02
NASDAQ : Health Technology
Prev Close 50.01
Open 50.05
Day Low/High 49.79 / 51.53
52 Wk Low/High 39.07 / 65.51
Volume 1.07M
Avg Volume 903.30K
Exchange NASDAQ
Shares Outstanding 137.27M
Market Cap 6.69B
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -

Interesting IONS Put And Call Options For September 21st

Interesting IONS Put And Call Options For September 21st

Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Webcast scheduled for Tuesday, August 7th at 11:30 a.m. Eastern Time

New England Journal Of Medicine Publishes Results From Pivotal Study Of TEGSEDI™ (inotersen) For The Treatment Of Hereditary ATTR Amyloidosis

New England Journal Of Medicine Publishes Results From Pivotal Study Of TEGSEDI™ (inotersen) For The Treatment Of Hereditary ATTR Amyloidosis

-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life-

Ionis Pharmaceuticals Appoints Damien McDevitt As Chief Business Officer

Ionis Pharmaceuticals Appoints Damien McDevitt As Chief Business Officer

CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For A Broad Range Of Neurological Diseases

Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For A Broad Range Of Neurological Diseases

CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Larger Than S&P 500 Component Leggett & Platt

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

New Data From IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction Of Disease-causing Protein And Improvement In Clinical Measures Of Huntington's Disease

First drug to demonstrate lowering of mutant huntingtin, the disease-causing protein, in people with Huntington's disease

Ionis Pharmaceuticals To Hold First Quarter 2018 Financial Results Webcast

Webcast scheduled for Friday, May 4 at 11:30 a.m. Eastern Time

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Ionis And Akcea Present New Data From ATTR Amyloidosis Program At 16th International Symposium On Amyloidosis

Ionis And Akcea Present New Data From ATTR Amyloidosis Program At 16th International Symposium On Amyloidosis

Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients;

Ionis And Akcea Partner To Commercialize Inotersen For HATTR

Ionis And Akcea Partner To Commercialize Inotersen For HATTR

Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis earns $30 million license fee

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ionis Pharmaceuticals Inc , where a total of 10,049 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.1% of IONS's average daily trading volume over the past month of 1.3 million shares.

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy...

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Jim Cramer says the market may be shaking off bad news and threats, but recent positivity is unusual. Don't speculate, be diversified and don't feel bad about taking profits.

TheStreet Quant Rating: D+ (Sell)